Results 51 to 60 of about 78,184 (307)

Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals [PDF]

, 2016
Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments.
Facco, Monica, Frezzato, Federica, Martini, Veronica, Semenzato, Gianpietro, Severin, Filippo, Trentin, Livio, Trimarco, Valentina, Visentin, Andrea   +7 more
core   +1 more source

Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity [PDF]

, 2005
During B-cell development in the mouse, Bruton tyrosine kinase (Btk) and the adaptor protein SLP-65 (Src homology 2 [SH2] domain-containing leukocyte protein of 65 kDa) limit the expansion and promote the differentiation of pre-B cells.
Dingjan, G.M. (Gemma), Hendriks, R.W. (Rudi), Jumaa, H., Kersseboom, R. (Rogier), Middendorp, S., Zijlstra, A.J.E. (Esther)   +5 more
core   +3 more sources

A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications

Molecules, 2023
Bruton tyrosine kinase (BTK) is an essential enzyme in the signaling pathway of the B-cell receptor (BCR) and is vital for the growth and activation of B-cells.
Qi Zhang, Changming Wen, Lijie Zhao, Yatao Wang   +3 more
doaj   +1 more source

Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model [PDF]

, 2014
X-linked agammaglobulinemia (XLA) is an inherited immunodeficiency that results from mutations within the gene encoding Bruton’s tyrosine kinase (BTK). Many XLA-associated mutations affect splicing of BTK pre-mRNA and severely impair B cell development ...
Behlke, Mark A, Berglöf, Anna, Bestas, Burcu, Blomberg, K Emelie M, El Andaloussi, Samir, Gait, Michael J, Gustafsson, Manuela O, Guterstam, Peter, Kharazi, Shabnam, Lundin, Karin E, Mohammad, Dara K, Moreno, Pedro M D, Månsson, Robert, Nordin, Joel Z, Piątosa, Barbara, Roberts, Thomas C, Saleh, Amer F, Smith, C I Edvard, Sutlu, Tolga, Wengel, Jesper, Wood, Matthew J A   +20 more
core   +1 more source

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Science
Increasing use of covalent and noncovalent inhibitors of Bruton’s tyrosine kinase (BTK) has elucidated a series of acquired drug-resistant BTK mutations in patients with B cell malignancies.
S. Montoya, J. Bourcier, M. Noviski, Hao Lu, Meghan C. Thompson, Alexandra Chirino, J. Jahn, Anya K. Sondhi, Stefan Gajewski, Ying Siow (May) Tan, Stephanie Yung, A. Urban, Eric Wang, Cuijuan Han, Xiaoli Mi, Won Jun Kim, Quinlan Sievers, Paul Auger, Hugo Bousquet, Nivetha Brathaban, Brandon Bravo, Melissa A. Gessner, C. Guiducci, James N. Iuliano, Tim Kane, Ratul Mukerji, P. J. Reddy, J. Powers, Mateo Sanchez Garcia de los Rios, Jordan Ye, Carla Barrientos Risso, Daniel Tsai, Gabriel Pardo, R. Notti, Alejandro Pardo, Maurizio Affer, Vindhya Nawaratne, T. Totiger, Camila Pena-Velasquez, Joanna M. Rhodes, A. Zelenetz, Alvaro J Alencar, L. Roeker, Sanjoy Mehta, Ralph Garippa, A. Linley, R. Soni, S. Skånland, Robert J. Brown, A. Mato, Gwenn H. Hansen, Omar Abdel-Wahab, Justin Taylor   +52 more
semanticscholar   +1 more source

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures

Frontiers in Immunology, 2021
Clinical development of BTK kinase inhibitors for treating autoimmune diseases has lagged behind development of these drugs for treating cancers, due in part from concerns over the lack of selectivity and associated toxicity profiles of first generation ...
G. Ringheim, M. Wampole, Kinsi Oberoi
semanticscholar   +1 more source

A vajdasági/délvidéki magyarok nemzeti identitása 1990-től napjainkig – II.

Metszetek, 2019
Tanulmányunk második részében bemutatjuk a vajdasági/délvidéki magyarok harmadik generációjának, az 1990 után színre lépettek nemzeti identitásának politikai-állampolgári és kulturális-történeti összetevőinek átalakulási folyamatait.
Teréz Kovács, Igor Kiss
doaj   +1 more source

BTK inhibitors in CLL: second-generation drugs and beyond

Blood Advances
BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom macroglobulinemia.
Constantine S. Tam, Philip A Thompson
semanticscholar   +1 more source

Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity.

Immunity, 2021
Monocytic-lineage inflammatory Ly6c+CD103+ dendritic cells (DCs) promote antitumor immunity, but these DCs are infrequent in tumors, even upon chemotherapy. Here, we examined how targeting pathways that inhibit the differentiation of inflammatory myeloid
Madhav Sharma, R. Pacholczyk, Huidong Shi, Z. Berrong, Y. Zakharia, A. Greco, Chang-Sheng Chang, S. Eathiraj, Eugene P Kennedy, T. Cash, R. Bollag, R. Kolhe, Ramses F. Sadek, T. McGaha, P. Rodriguez, J. Mandula, B. Blazar, Theodore S. Johnson, D. Munn   +18 more
semanticscholar   +1 more source

Interaction between the Btk PH Domain and Phosphatidylinositol-3,4,5-trisphosphate Directly Regulates Btk [PDF]

Journal of Biological Chemistry, 2001
Bruton's tyrosine kinase (Btk) binds to phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P(3)) through the Btk pleckstrin homology (PH) domain, an interaction thought to be required for Btk membrane translocation during B cell receptor signaling. Here, we report that interaction of PtdIns-3,4,5-P(3) with the PH domain of Btk directly induces Btk ...
K, Saito, A M, Scharenberg, J P, Kinet
openaire   +2 more sources